AGN - FDA Approves Biohaven's Migraine Treatment Nurtec ODT
The Food and Drug Administration (FDA) has approved Biohaven Pharmaceutical's (NYSE: BHVN) Nurtec ODT as an acute migraine treatment. Shares of the company were up 7.8% at 7:08 p.m. EST in after-hours trading after falling 8.5% during the regular session.
The drug melts in your mouth, literally -- the ODT stands for orally disintegrating tablet. Biohaven plans to have the drug in pharmacies in early March.
Nurtec ODT is a calcitonin gene-related peptide (CGRP) receptor antagonist in the same class as Allergan's (NYSE: AGN) Ubrelvy, which was approved in December. Ubrelvy is in typical tablet form, which most patients would take with water, making it slightly less convenient than an ODT.